Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;8(5):351-9.
doi: 10.1177/1758834016657071. Epub 2016 Jul 10.

Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Poornima Saha  1 , Rita Nanda  2
Affiliations
Review

Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Poornima Saha et al. Ther Adv Med Oncol. 2016 Sep.

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of TNBC, and chemotherapy remains the standard of care. Gene expression profiling has identified six distinct molecular subtypes of TNBC. The identification of novel targets, coupled with the development of therapies for different subsets of TNBC, holds great promise for the future treatment of this aggressive form of breast cancer. This review focuses on novel therapies in development for the treatment of TNBC.

Keywords: targeted therapy; therapeutic targets in triple-negative breast cancer; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Adams S., Diamond J., Hamilton E., Pohlmann P., Tolaney S., Molinero L., et al. (2015) Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. Poster presented at San Antonio Breast Cancer Symposium, 8–12 December 2015, San Antonio, TX, USA.
    1. Ambrogi F., Fornili M., Boracchi P., Trerotola M., Relli V., Simeone P., et al. (2014) Trop-2 is a determinant of breast cancer survival. PLoS One 9: e96993. - PMC - PubMed
    1. Bardia A., Diamond J., Mayer I., Starodub A., Moroose R., Isakoff S., et al. (2015) Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC. Poster presented at San Antonio Breast Cancer Symposium, 8–12 December 2015, San Antonio, TX, USA.
    1. Bendell J., Saleh M., Rose A., Siegel P., Hart L., Sirpal S., et al. (2014) Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol 32: 3619–3625. - PubMed
    1. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375–379. - PubMed